Ocata Therapeutics Inc

Ocata Therapeutics — IPO Roadshow (December 2014)

32 slides from Ocata Therapeutics's IPO roadshow presentation, Dec 19, 2014

  1. Slide 1: Public Offering December 2014

    Public Offering December 2014

  2. Slide 2: Cautionary Statement Concerning Forward-Looking Statements

    Cautionary Statement Concerning Forward-Looking Statements Ocata Therapeutics Inc. (“Ocata” or “the Company”) has filed a registration statement (including a prospectus and a preliminary prospectus supplement) with the Securities and Exchange Commission (“SEC”) for the offering to which this present

  3. Slide 3: Ocata's Regenerative Ophthalmology Research Poised to Deliver Transformative Therapies

    Ocata's Regenerative Ophthalmology™ Research is Poised to Deliver Transformative New Therapies for Macular Degeneration and Other High Medical Need Diseases of the Eye Stargardt’s Macular Degeneration (SMD) is an orphan disease with no available treatment Leading form of inherited juvenile onset mac

  4. Slide 4: First Long-term Evidence of Safety and Signs of Improvement in Vision with RPE Cells

    Ocata Therapeutics Provides the First Long-term Evidence of Safety and Signs of Improvement in Vision with Transplantation of RPE Cells “What we did is transplant the cells into patients who have a disease where those particular cells are dying; and we replaced those dying tissues with new tissue th

  5. Slide 5: Addressing Macular Degeneration with Groundbreaking RPE Therapy

    Addressing Macular Degeneration with Groundbreaking RPE Therapy The Regenerative Ophthalmology™ Company Safety observed, in addition to anatomical and functional evidence of repair and restoration in Phase 1 trials for dry AMD and SMD Data published in The Lancet, October 14, 2014 Initiating Phase 2

  6. Slide 6: Stem Cells are the Starting Material but Fully Differentiated Cells are the Treatment

    Stem Cells are the Starting Material but Fully Differentiated Cells are the Treatment Pluripotent Stem Cells Starting Source World Leaders in Terminal Differentiation of Pluripotent to Target Cells Induce pluripotent stem cells into terminally differentiated cells to become the target tissue, such a

  7. Slide 7: RPE Damage and Subsequent Photoreceptor Degeneration Leads to Loss of Central Visual Acuity

    RPE Damage and Subsequent Photoreceptor Degeneration Leads to Loss of Central Visual Acuity Patients suffering from dry AMD and SMD have no effective treatment options

  8. Slide 8: Retinal Pigment Epithelium is Vital for Photoreceptor Health

    Retinal Pigment Epithelium is Vital for Photoreceptor Health Failure of RPE Causes Macular Degeneration Ocata's Proprietary RPE Transplant Therapy Addresses These Forms of Macular Degeneration Targeting Orphan Disease (SMD) and Large Potential Markets (e.g. Dry AMD and MMD) Disease Pathophysiology P

  9. Slide 9: Ophthalmic Development Pipeline Includes SMD, Dry AMD and MMD

    Ophthalmic Development Pipeline Includes SMD, Dry AMD and MMD Pre-clinical IND Phase 1 Phase 2 SMD Dry AMD MMD Photoreceptors Ganglion Cells Cornea Phase 2 interim data for RPE Programs Opportunity for additional IND’s Potential European launch for Stargardt’s Macular Degeneration in 2019 Multiple O

  10. Slide 10: The Eye is Well-Suited for Cellular Transplantation

    Immune privileged Less prone to rejection Compact Structure Relatively small doses required to treat Straightforward delivery using currently available technology Validated tools for clinical outcome assessment The Eye is Well-Suited for Cellular Transplantation

  11. Slide 11: RPE Market Dynamics for Stargardt's Macular Degeneration

    RPE Market Dynamics for Stargardt’s Macular Degeneration Orphan Disease with an Estimated Prevalence of 1:10,000 (~31,600 in the US) Three main subtypes of patients that physicians observe Fast deterioration Slow deterioration Rod and cone dystrophy Stargardt’s patients are primarily diagnosed and m

  12. Slide 12: Market Dynamics Age-related Macular Degeneration

    Market Dynamics Age-related Macular Degeneration ~1.8m Dry AMD Patients Diagnosed Every Year in the USA In the late form of dry AMD, patients can progress to geographic atrophy (GA) – GA progresses slowly and leads to the death of the photoreceptors. Approximately 110,000-165,000 Cases of Advanced D

  13. Slide 13: SMD, Dry AMD and MMD are Specialized Opportunities, Feasible for an Emerging Biotech

    Well-defined prescriber base Patients are referred to retinal specialists (~2,500 in the US of which ~1,500- 2,000 are surgical RS) who diagnose and manage subsequent patient care Vitreoretinal surgeons will be responsible for the majority of procedures Physician outreach can be readily achieved wit

  14. Slide 14: Clinical Programs RPE for SMD, Dry AMD and MMD

    Clinical Programs RPE for SMD, Dry AMD and MMD

  15. Slide 15: Retinal Pigment Epithelium: Vital for Photoreceptor Health

    Required for vision and maintenance of photoreceptor health Delivers and metabolizes Vitamin A Recycles photopigments Phagocytosis of photoreceptor outer segments Transport of metabolic waste from retina to choriocapillaris Absorbs stray light for improved image resolution Secretes growth and surviv

  16. Slide 16: Anatomical Overview

    Anatomical Overview Normal Macula Fovea Retinal arteries & veins Optic nerve & “2h OCATA,

  17. Slide 17: Macular Degenerative Diseases

    Macular Degenerative Diseases Normal Dry AMD SMD MMD

  18. Slide 18: Visual Physiology: Normal

    Visual Physiology: Normal t Peripheral retina Macular region Neural signal to the brain Photoreceptors “1 OCATA

  19. Slide 19: Visual Physiology: Macular Degeneration

    Visual Physiology: Macular Degeneration

  20. Slide 20: Thesis of RPE Transplantation: Restoration of Anatomy & Function

    Thesis of RPE Transplantation: Restoration of Anatomy & Function Neural signal restored

  21. Slide 21: Phase 1/2 Study Design: 38 Patients Treated, Safety Well Characterized

    Open-label, non-randomized, sequential multi-center trial 4 dose cohorts Poor Vision Initially HM -> not better than 20/400; given safety, FDA supportive of treating not better than 20/100 Sequential enrollment of dose groups Independent DSMB review of safety First subject in cohort: 6 weeks after t

  22. Slide 22: Phase 1 Trials: Evidence of Engraftment

    Patches of increasing subretinal, pigmented cellular tissue consistent with transplanted, integrated RPE were observed in most subjects Images of transplanted tissue (autofluorescence, optical coherence tomography) suggest physiologic polarization and function of transplanted RPE Phase 1 Trials: Evi

  23. Slide 23: BCVA Improved in Both Patient Populations and was Sustained

    BCVA Improved in Both Patient Populations and was Sustained Success in Phase 1/2 Studies Supports Investment in Proof-of-Concept Trials Days After Transplant Treated Eye Untreated Eye SMD (N=5) 0 Dry AMD (N=8) 0 Median Change in Best Corrected Visual Acuity (Letters) 0 31 91 182 366 -5 0 5 10 15 20

  24. Slide 24: Translating Phase Success into an Optimized Phase Plan

    Translating Phase 1 Success into an Optimized Phase 2 Plan SMD Phase 2 Dry AMD Phase 2 MMD Phase 1 N 100 45 12 Initiation January 2015 April 2015 January 2016 Objective Efficacy and safety Assessment of relevant functional and anatomic parameters Safety evaluation of systemic immunosuppressive regim

  25. Slide 25: Cells are Transplanted via Common Surgical Technique

    Vitrectomy: Commonly performed outpatient procedure (~300,000/annually) by approximately 2,000 surgeons in the US Sub-retinal administration is a ~90 second “add-on” Builds on commonly practiced eye procedures and referral patterns Cells are Transplanted via Common Surgical Technique

  26. Slide 26: Additional Cell Types in Development to Address a Spectrum of Ocular Disorders

    1 2 3 4 Additional Cell Types in Development to Address a Spectrum of Ocular Disorders Photoreceptor Progenitor Cells Macular Degeneration - dry AMD, SMD, MMD Retinitis Pigmentosa Retinal Ganglion Progenitor Cells Glaucoma Mesenchymal Stem Cells Uveitis Management of Ocular Surfaces Corneal Endothel

  27. Slide 27: Operations, Finance and Corporate

    Operations, Finance and Corporate

  28. Slide 28: Ocata Has Invested Heavily to Own Manufacturing Process in cGMP Environment

    Ocata Therapeutics has Invested Heavily to Own Manufacturing Process in cGMP Environment Continued Investment and Advances in Manufacturing and Delivery Generates Expansion of IP Estate Cryopreserved – inexhaustible replicative capacity starting material, stored at ACT and in remote location Master

  29. Slide 29: IP Coverage From Stem Cell Line to Patient Treatment

    IP Coverage From Stem Cell Line to Patient Treatment Single Blastomere Derivation of hESCs Methods of Manufacturing hESC-derived RPE cells Product Release Assays Pharmaceutical Preparations Methods-of-Treatment 3 Patent Families 13 Issued Patents 26 Pending Applications Core Patent expiry – 2031 (wi

  30. Slide 30: Ocata Therapeutics Financial Overview

    Trades on OTC – OCAT September 30, 2014 cash balance - $7.8m Currently funded from $30m equity line with Lincoln Park Capital, of which ~$20m remains ~35m shares outstanding (fully diluted) no preferred stock no debt Active Dialogue with Nasdaq Ocata Therapeutics Financial Overview

  31. Slide 31: Potential Milestones

    Potential Milestones: Next 18 – 24 Months Year Quarter Milestone 2015 Q1 SMD P2: First subject treated Up-listing of company stock to Nasdaq Publication of data in Asian patients (SMD & AMD) Q2 AMD P2: First subject treated Q4 AMD P2: First 15 subjects with 3 month of data Partnership of non-core as

  32. Slide 32: The World Leader in Regenerative Ophthalmology

    Initiating Phase 2 with novel, potentially curative therapy in areas where no approved products exist today (Dry AMD/SMD) Dry AMD is a potential blockbuster indication – a precursor to Wet AMD where Treatments include Eylea (Regeneron) and Lucentis (Novartis/Roche) Safety observed, in addition to an

Ocata Therapeutics — IPO Roadshow (December 2014) on 6ix